Tovorafenib
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low-grade Glioma
Conditions
Low-grade Glioma
Trial Timeline
Feb 16, 2026 → Jul 31, 2030
NCT ID
NCT07441707About Tovorafenib
Tovorafenib is a phase 1 stage product being developed by Ipsen for Low-grade Glioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441707. Target conditions include Low-grade Glioma.
What happened to similar drugs?
0 of 3 similar drugs in Low-grade Glioma were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441707 | Phase 1 | Recruiting |
Competing Products
13 competing products in Low-grade Glioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 26 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Everolimus | Novartis | Phase 2 | 35 |
| MEK162, MEK inhibitor; oral + Physician's choice chemotherapy | Pfizer | Phase 3 | 32 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 35 |
| rituximab | Biogen | Phase 3 | 37 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 36 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 41 |
| DAY101 | Day One Biopharmaceuticals | Phase 1 | 23 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 20 |
| TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD | Tyra Biosciences | Phase 2 | 36 |
| rhuFlt3L/CDX-301 + Poly-ICLC | Celldex Therapeutics | Phase 1/2 | 26 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 25 |